Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Abstract Mantle cell lymphoma (MCL) is a clinically heterogeneous B‐cell neoplasm with unique clinicopathological features, accounting for 5% of all non‐Hodgkin lymphoma. Although for many chemoimmunotherapy can lead to durable remissions, those with poor baseline prognostic factors, namely blastoid morphology, TP53 aberrancy and Ki67 >30%, will have less durable responses to conventional therapies. With this in mind, clinical trials have focused on novel targeted therapies to improve outcomes. This review details the recent advances in the understanding of MCL biology and outlines the recommended diagnostic strategies and evidence‐based approaches to treatment.